Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer


Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer

Mont-Saint-Guibert, Belgium – April 11, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Dr. Maurits S. Boon, MD as Chief Medical Officer.

Dr. Boon joins Nyxoah from the Thomas Jefferson University, where he will continue part time as a professor and Vice Chairman, Education. He is dual board-certified in otolaryngology – head and neck surgery, as well as sleep medicine. Dr. Boon is one of two sleep surgeons with Jefferson Health to pioneer the use of hypoglossal nerve stimulation therapy (HGNS) and is internationally recognized as one of the most experienced surgeons performing HGNS procedures. He has lectured worldwide on obstructive sleep apnea, has numerous publications and is co-editor of the first book on HGNS.

“As an academic physician who has dedicated my professional career to the care of patients with sleep disordered breathing, I was privileged to participate in the DREAM U.S. pivotal trial. I was initially impressed by the results I saw in my patients and then equally impressed by the data that were recently reported. As such, I am honored to have been offered a position to join Nyxoah at such an exciting time. Bilateral hypoglossal nerve stimulation with Genio has tremendous potential and I am thrilled to work with their talented team to make a meaningful impact on the lives of patients with obstructive sleep apnea,” commented Dr. Boon.

“I could not be more excited to have Dr. Boon join Nyxoah. He is one of the pioneers in hypoglossal nerve stimulation and his decision to become Nyxoah’s Chief Medical Officer reflects Genio’s ability to improve the lives of OSA patients,” commented Olivier Taelman, Chief Executive Officer. “Dr. Boon will play a critical role as we prepare to enter the U.S. market and achieve our mission of making sleep simple again.”

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313


Attachment

  • ENGLISH_Nyxoah Appoints Maurits Boon MD as Chief Medical Officer


Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer

THỦ THUẬT HAY

Cách sử dụng Efficiency trên trình duyệt Microsoft Edge

Bạn đang sử dụng Microsoft Edge để duyệt web và muốn tăng hiệu suất của trình duyệt. Vậy thì chỉ cần bật chế độ Efficiency mode theo cách dưới đây.

Lập kế hoạch với công cụ S Planner trên Samsung Galaxy On7

S Planner là ứng dụng được tích hợp sẵn trên Samsung Galaxy On7, cho phép người dùng dễ dàng tạo ghi chú cho những sự kiện và kế hoạch sắp thực hiện.

Những cổng kết nối hình ảnh trường gặp trên PC, Laptop, Card màn hình

Với chuẩn HDMI bạn có thể truyền đồng thời hình ảnh và âm thanh trên 1 cáp HDMI với chất lượng cao, chuẩn HDMI hiện nay có thể truyền hình ảnh với độ phân giải lên đến 4K cùng với 8 kênh âm thanh.

Cách giải phóng dung lượng trên thiết bị trên Windows 10 Spring Creators Update

Windows 10 Spring Creators Update đã cải tiến tính năng mang tên Storage Sense. Tính năng này sẽ giúp tự động giải phóng dung lượng trên thiết bị của bạn bằng cách xóa các tệp tạm thời do phần mềm tạo ra và các tệp nằm

3 cách bật, tắt High contrast, chế độ tương phản win 10(màn hình đen )

High contrast là chế độ tương phản cao trên Windows 10, nếu như vô tình bật High contrast trên Windows 10 lên mà không biết cách tắt sẽ thực sự là một thảm họa vì nó sẽ khiến mắt cua bạn rối loạn hơn. 3 cách sau đây sẽ

ĐÁNH GIÁ NHANH

Trên tay Samsung Gear Iconic 2: pin lâu hơn, sạc nhanh, bỏ cảm biến HR

Samsung Gear IconX 2018 có nhiều thay đổi bên trong so với thế hệ trước. Quan trọng nhất là thời lượng pin từ dùng được khoảng hơn 1 giờ ở thế hệ trước đã tăng lên khoảng 4 giờ nói chuyện, 5 giờ nghe nhạc... ở thế hệ

Đánh giá Honda CR-V L 2018: Có thật sự đáng với giá tiền?

Tại Việt Nam, Honda CR-V có mặt từ năm 2008 và đến nay đã bán ra khoảng 25.000 xe. Honda CR-V cũng luôn là cái tên được săn đón cả trên thị trường xe mới và xe cũ. Chỉ cần bỏ ra vài phút tra cứu,

Đánh giá Dell XPS 13 Developer Edition: Core i7, Ram 16 GB đầy sức mạnh

Dell đã thực hiện một số tinh chỉnh ví dụ như: Webcam nay có hỗ trợ Windows Hello, một phiên bản màu trắng tuyết, tốc độ RAM được nâng từ 3.733 MHz lên 4.267 MHz, phần touchpad cho cảm giác nhấn êm hơn và tốc độ đọc